KIM-1 antagonists and use to modulate immune system
AssigneeBiogen Idec MA Inc.
InventorPaul D. Rennert
Life of this patent
Estimating the term…
Abstract
The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-γ by lymphocytes or other immune cells in a mammal. Inhibition of IFN-γ is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.
Claims4
A method of treating an immunological disorder in a subject, the method comprising administering to the subject an effective amount of a composition comprising an antagonist antibody or antigen-binding fragment thereof that binds to KIM-1, wherein the immunological disorder is an inflammatory bowel disease.
Dependencies are inferred from the claim text.